Suchergebnisse - "Yan, Wenting"

PubPharm (23)

1

Exposure to di-2-ethylhexyl phthalate and breast neoplasm incidence : A cohort study

enthalten in: The Science of the total environment | 2024

von Tang, L. | Wang, Y. | Yan, W. | +7

2

Two Hematological Markers Predicting the Efficacy and Prognosis of Neoadjuvant Chemotherapy Using Lobaplatin Against Triple-Negative Breast Cancer

enthalten in: The oncologist | 2024

von Wang, C. | Shi, Q. | Zhang, G. | +10

3

Rotating shift work Is Associated with increased risk of thyroid carcinoma ： an ecological study of 178905 workers in 35 European countries between 2000 and 2015

enthalten in: ResearchSquare.com | 2023

von Yang, Y. | Yan, W. | Han, S. | +3

4

Resilience Evaluation and Enhancement Strategy of Distribution Network Considering Impact of Seismic Attack on Transportation Networks

in: Shanghai Jiaotong Daxue xuebao | 2023

von YAN Wenting, Y.

5

Association of Long-term Oncologic Prognosis With Minimal Access Breast Surgery vs Conventional Breast Surgery

enthalten in: JAMA surgery | 2022

von Wan, A. | Liang, Y. | Chen, L. | +15

CommentIn: JAMA Surg. 2023 Jul 1;158(7):775-776. - PMID 36920378

6

Bromide impairs the circadian clock and glycolytic homeostasis via disruption of autophagy in rat H9C2 cardiomyocytes

enthalten in: ResearchSquare.com | 2022

von Jiang, Y. | Gu, Y. | Xu, H. | +5

7

Bromide impairs the circadian clock and glycolytic homeostasis via disruption of autophagy in rat H9C2 cardiomyocytes

enthalten in: ResearchSquare.com | 2022

von Jiang, Y. | Gu, Y. | Xu, H. | +5

8

Lobaplatin-based neoadjuvant chemotherapy for triple-negative breast cancer : a 5-year follow-up of a randomized, open-label, phase II trial

enthalten in: Therapeutic advances in medical oncology | 2022

von Yan, W. | Wu, X. | Wang, S. | +7

9

Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer : A Narrative Review

enthalten in: Frontiers in pharmacology | 2021

von Tian, H. | Ma, D. | Tan, X. | +8

10

Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I-III HER2-Positive Breast Cancer : A Phase II Clinical Trial

enthalten in: The oncologist | 2020

von Xuhong, J. | Qi, X. | Tang, P. | +12